Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...

Pharmacogenomics: Identification of New Drug Targets

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...

Pharmacogenetics of Drug Metabolism: Overview

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...

Principles of Pharmacogenetics: Types of Genetic Variants

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...

Pharmacovigilance

Pharmacovigilance

Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Stress-Based biomechanical modeling in hip dysplasia Surgery: A scoping review.

Journal of biomechanics·2026

Same author

From theory to tissue: Constitutive modeling and underlying assumptions in cartilage biomechanics.

Journal of the mechanical behavior of biomedical materials·2026

Same author

Late-onset severe neutropenia in patients with relapsing remitting multiple sclerosis treated with ocrelizumab: case report and literature review.

Frontiers in neuroscience·2025

Same author

Extraosseous Ewing sarcoma of the common fibular nerve.

Practical neurology·2025

Same author

Lost in Cognition: Paraneoplastic Rhombencephalitis With Anti-Ri/Antineuronal Nuclear Antibody Type 2 (ANNA-2) Antibodies Presenting as Rapid-Onset Cognitive Decline and Ophthalmoplegia-Ataxia With Reversible Brainstem Lesion.

Cureus·2025

Same author

Exploring the impact of an interventional approach to resident teaching in anesthesiology clerkships.

Medical education online·2025

Search research articles

Related Experiment Video

Updated: Apr 28, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

Pharmacogenovigilance: a pharmacogenomics pharmacovigilance program.

Zeinab Awada¹, Nathalie Khoueiry Zgheib

¹Biomedical Sciences, Faculty of Medicine, American University of Beirut, Beirut, Lebanon.

Pharmacogenomics

|June 5, 2014

Summary

Pharmacovigilance detects adverse drug events. Integrating pharmacogenomics into pharmacovigilance programs in primary care can improve data collection for personalized medicine applications.

Keywords:

adverse drug events electronic medical records pharmacogenomics pharmacogenovigilance pharmacovigilance primary care

More Related Videos

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Published on: June 21, 2018

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

Related Experiment Videos

Last Updated: Apr 28, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Published on: June 21, 2018

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

Area of Science:

Pharmacogenomics and Pharmacovigilance
Clinical Pharmacology
Healthcare Informatics

Background:

Pharmacovigilance is crucial for identifying postmarketing adverse drug events.
Pharmacogenomics offers potential for personalized drug therapy.
Integrating these fields can enhance drug safety and efficacy.

Purpose of the Study:

To review the importance of pharmacovigilance in detecting adverse drug events.
To explore the potential of developing pharmacogenovigilance programs.
To propose a framework for implementing such programs in primary healthcare.

Main Methods:

Literature review on pharmacovigilance and pharmacogenomics.
Proposal for integrating pharmacogenomics with electronic medical records in primary care.
Focus on systems with large patient populations and common drug prescriptions.

Main Results:

Pharmacovigilance systems are essential for postmarketing surveillance.
Pharmacogenovigilance programs can leverage existing healthcare infrastructure.
Integration requires careful design for effective data collection and interpretation.

Conclusions:

Developing pharmacogenovigilance programs is feasible and beneficial.
Primary healthcare settings are suitable for initial implementation.
These programs can enhance the clinical application of pharmacogenomics testing.